Overview

Adenosine and calcium antagonists demonstrate equivalent efficacy in the conversion of stable supraventricular tachycardia (SVT) to sinus rhythm. The choice between them is not based on success rate, but on their different safety and pharmacokinetic profiles. Adenosine is the first-line drug recommended by clinical guidelines due to its ultra-short half-life of less than 10 seconds, which ensures that its common adverse effects (chest pain, dyspnea) are extremely brief and self-limiting. Its action is almost immediate, causing a transient block of the AV node that effectively interrupts the arrhythmia circuit. On the other hand, verapamil has a slower onset of action and a prolonged duration of effect. Its main risk is hypotension, which may be sustained and require additional management. Therefore, it is considered a second-line alternative, ideal for patients in whom adenosine is contraindicated or has proven ineffective. In conclusion, the preference for adenosine is due to its superior safety profile, not to greater efficacy, consolidating it as the most prudent option for most patients.

Full Product Details

9786209330674

Table of Contents

Reviews

Author Information

Tab Content 6

Countries Available